Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

Liu, Ying; Lu, Jiajing; Zhong, Xiaoyuan; Yu, Ying-Yuan; Yu, Na; Wang, Yu; Xie, Yonggang; Ding, Yangfeng; Shi, Yu

doi:10.2147/ccid.s387759

Cited by 12 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall cumulative drug survival (DS) was high, with only a minimal decline over time, attaining 91.6% after 12 months of therapy, 87.0% after 24 months, and 85.5% after 36 months of therapy. Our data correlate with other RWE in the assessment of one-year [ 43 , 47 ], two-year drug survival on treatment [ 15 , 22 , 44 – 46 ]. Three-year survival data on treatment have not yet been published.…”

Section: Discussionsupporting

confidence: 81%

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry

Hugo

Kojanová

Turkova

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Background Real-world data on the long-term use of guselkumab for treatment of psoriasis are still limited. Objective We aimed to evaluate long-term efficacy, safety, and drug survival of guselkumab in a real-world setting. Methods This is a retrospective study analyzing Czech Republic registry (BIOREP) data of patients treated with guselkumab. Results In total, 333 patients were included. Improvement in Psoriasis Area and Severity Index (PASI) score was significant. Mean PASI score decreased from 16 at baseline to 0.7, 0.9, and 0.8 after 12, 24, and 36 months, respectively. Absolute PASI scores of ≤ 3 and ≤ 1 were achieved in 93.9% and 77.9%, 94.2% and 71.0%, and 94.8% and 70.7% of patients after 12, 24, and 36 months, respectively. Response PASI 90 and PASI 100 were attained in 81.8% and 57.1%, 75.4% and 50.7%, and 75.9% and 55.2% of patients after 12, 24, and 36 months, respectively. The percentage of patients achieving PASI 90 and PASI 100 responses was higher throughout the study in bio-naive and in normal-weight patients, while presence of psoriatic arthritis had no influence. Improvement in Dermatology Life Quality Index (DLQI) score was also significant; mean DLQI score decreased from 14.2 at baseline to 0.9, 1.0, and 0.7 after 12, 24, and 36 months, respectively. Patients with PASI 100 had lower mean DLQI throughout the study compared with patients with PASI 90. Major reason for discontinuation was loss of effectiveness in 7.1% of patients, while only 0.6% were due to adverse events. Overall cumulative drug survival was high, with only a minimal decline over time, reaching 91.6%, 87.0%, and 85.5% after 12, 24, and 36 months, respectively. Drug survival was not affected by previous biological treatment, patient weight, or presence of psoriatic arthritis. Conclusions This real-world study demonstrated the long-term effectiveness, good safety profile, and high drug survival of guselkumab treatment over a period of 36 months.

show abstract

Section: Discussionsupporting

confidence: 81%

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry

Hugo

Kojanová

Turkova

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Summary drug survival curves in blue, separate studies in grey. A Secukinumab [ 24 – 26 , 33 , 34 , 39 – 41 , 44 , 46 , 48 , 50 , 51 , 53 , 62 , 64 , 68 , 70 , 72 , 74 , 80 – 85 ], B ixekizumab [ 23 , 32 , 33 , 39 , 40 , 42 – 44 , 46 , 49 , 62 , 70 , 81 , 84 , 85 ], C brodalumab [ 39 , 40 , 58 , 62 , 84 – 87 ], D guselkumab [ 29 , 30 , 33 , 35 , 37 , 43 , 44 , 50 , 59 , 70 , 84 , 85 , 88 , 89 ], E risankizumab [ 27 , 50 , 84 , 85 , 90 ], ...…”

Section: Resultsmentioning

confidence: 99%

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis

Thomas,

Barenbrug,

Hannink

et al. 2024

Drugs

View full text Add to dashboard Cite

Background and Objective The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently used outcome to assess drug performance in practice. An overview of the available drug survival studies regarding IL-17 and IL-23 inhibitors is lacking. Therefore, our objective was to assess the drug survival of IL-17 and IL-23 inhibitors for psoriasis. Methods A search of PubMed, Embase, Cochrane Library and Web of Science was conducted (last search 27 December, 2023). Inclusion criteria were (1) cohort study; (2) patients aged ≥ 18 years with plaque psoriasis; and (3) evaluation of drug survival of at least one of the IL-17 and IL-23 inhibitors. Exclusion criteria were: primary focus on patients with psoriatic arthritis, fewer than ten study subjects and another language than English. The Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline was followed. Survival probabilities at monthly intervals were extracted from Kaplan–Meier curves using a semi-automated tool. Data were pooled using a non-parametric random-effects model to retrieve distribution-free summary survival curves. Summary drug survival curves were constructed per biologic for different discontinuation reasons: overall, ineffectiveness and adverse events, and split for the effect modifier biologic naivety. Results were analysed separately for registry/electronic health record data and for pharmacy/claims data. Results A total of 69 studies aggregating drug survival outcomes of 48,704 patients on secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, and tildrakizumab were included. Summary drug survival estimates of registry/electronic health record studies for overall, ineffectiveness and adverse event related drug survival were high (all point estimates ≥ 0.8 at year 1) for included biologics, with highest estimates for guselkumab and risankizumab. All estimates for drug survival were higher in biologic naive than in experienced patients. Estimates of pharmacy/claims databases were substantially lower than estimates from the primary analyses based on registry/electronic health record data. Conclusions This meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies. Supplementary Information The online version contains supplementary material available at 10.1007/s40265-024-02028-1.

show abstract

“…Real‐world experiences are also limited especially for patients with PASI less than 10. In a 52‐week Chinese single‐center retrospective study, overall cumulative drug survival rate of secukinumab was 63.0% 2 . It is worth noting that significant proportion of patients are using half‐dose secukinumab in Chinese population, 3,4 and for those patients with inadequate responses, an alternative and affordable choice with comparable effectiveness is imperative.…”

Section: Introductionmentioning

confidence: 99%

Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study

Hsieh,

Tseng,

Tsai

2023

Experimental Dermatology

View full text Add to dashboard Cite

In the registration trial of risankizumab for patients with moderate‐to‐severe psoriasis in Japan, similar Psoriasis Area Severity Index (PASI) responses were observed for 75 mg or 150 mg risankizumab at most time points up to 52 weeks, except for PASI 100 at week 16. The use of 75 mg risankizumab offers an attractive option considering the high cost of risankizumab. However, it is unknown whether patients with mild‐to‐moderate psoriasis respond similarly, and the efficacy data of non‐Japanese patients is also lacking. We retrospectively included 30 consecutive Chinese patients receiving half‐dose (75 mg) risankizumab as scheduled up to 52 weeks. Compared with biologic‐experienced group, biologic‐naive group had a significantly higher PASI 50/75/90/100 achievement (p = 0.0098/0.0039/0.0016/0.0054) at week 52. PASI 50/75/90/100 curves in biologic‐naive group (p = 0.0117/0.0239/0.0143/0.0269) were also significantly higher when analysed generalized estimating equations (GEE) model. Though there was no statistically significant difference in terms of PASI 50/75/90/100 responses at any time points between those with body weight ≦ 65 kg and those >65 kg, a tendency of secondary failure was noted in those >65 kg from week 40 onwards. Patients who were both biologic‐naive and weighed ≦ 65 kg achieved sustained PASI 50/75/90 responses from week 16/28/40 onwards, respectively, indicating that they could be considered as potential candidates for 75 mg risankizumab. Though PASI 75 curve in patients without diabetes mellitus (DM) surpassed that in patient without DM, curves of other parameters did not reach significance when analysed by GEE model. There was no HBV, HCV or TB reactivation, nor other new safety signals during the 52‐week observational period. Providing risankizumab with flexible dosing options is beneficial in clinical practice considering the high cost of this medication.

show abstract

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

Cited by 12 publications

References 21 publications

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis

Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study

Contact Info

Product

Resources

About